Armata Pharmaceuticals is a Hold until Phase 3 AP-SA02 data, given a funding-dependent profile and limited margin for error.
Altimmune closed a $75M direct offering to fund Phase 3 pemvidutide trials for MASH, leveraging recent positive Phase 2b data and FDA Breakthrough Therapy status. Pemvidutide’s dual GLP-1/glucagon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results